Pityriasis Rosea-Like Eruption by Covid-19 Infection: A New Case Report

Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)

Imatinib mesylate (Gleevec™, STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use has been associated with various adverse cutaneous reactions, pityriasis rosea-like drug eruptions are rare. Here, we report a case of pityriasis rosea-like drug erupti...

Covid-19 infection in kidney transplant recipients: a case report

Atypical Pityriasis rosea in a black child: a case report

INTRODUCTION Pityriasis rosea is a self-limited inflammatory condition of the skin that mostly affects healthy children and adolescents. Atypical cases of Pityriasis rosea are fairly common and less readily recognized than typical eruptions, and may pose a diagnostic challenge. CASE PRESENTATION We report the case of a 12-year-old black child that developed an intense pruritic papular eruptio...

Ibrutinib-associated pityriasis rosea–like rash

CLL: chronic lymphocytic leukemia PR: pityriasis rosea EGFR: epidermal growth factor receptor PDGFR: platelet-derived growth factor receptor I brutinib, a Bruton tyrosine kinase inhibitor, is a new oral agent approved for the treatment of chronic lymphocytic leukemia (CLL). Ibrutinib is well-tolerated, with the majority of its adverse events within grade 1 or 2 severity. The most common nonhema...

Pityriasis rosea.

T HE Medical Research Council's investigation into pityriasis rosea in 1959 has already been published (Proc. roy. Soc. Med., 55, 556). This second investigation, based on a very simple questionnaire, has produced some additional information, but has not altogether solved the question put, namely "What is the cause of this disease?" Much interest was shown. In 1964, 180 observers notified 531 c...